Aprotinin (Trasylol) does not reduce bleeding in primary total hip arthroplasty.
This is a randomized, double-blind, controlled study of the effects of aprotinin (Trasylol) during primary total hip arthroplasty. Sixty patients were randomized to receive either 1.5 x 10(6) KIU of aprotinin or a similar volume of normal saline as a bolus preoperatively. Blood loss was measured from the femoral canal at the time of surgery. An estimate of the total blood loss during the operation was made, and the transfusion requirement was recorded. There was no significant difference between the groups in terms of total blood loss, postoperative hemoglobin, or transfusion requirement. In the group that received aprotinin, there was a trend toward reduced blood loss from the femoral canal, but this was not statistically significant. The results of this study do not support the routine use of aprotinin in primary total hip arthroplasty.
Langdown
A J
AJ
Trauma Service, John Radcliffe Hospital, Oxford, United Kingdom.
Field
J
J
Grote
J
J
Himayat
H
H
D000368:Aged; D007611:Aprotinin / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001803:Blood Transfusion; D004311:Double-Blind Method; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D015207:Osteoarthritis, Hip / Q000601:surgery
D006490:Hemostatics; D007611:Aprotinin